Phase IIa Pilot Study Evaluating the Efficacy of a Monoclonal Antibody and Vaccine-based Post-exposure Prophylaxis Strategy in High-risk Contact Cases of Ebola Virus Disease Infection
Latest Information Update: 06 Oct 2023
At a glance
- Drugs Ansuvimab (Primary) ; RVSV-S-GP/VP40 vaccine (Primary)
- Indications Ebola virus infections
- Focus Pharmacodynamics; Therapeutic Use
- Acronyms PROVAE
- 14 Oct 2021 Planned initiation date changed from 1 Apr 2021 to 17 Oct 2021.
- 01 Apr 2021 New trial record